Robert J. Lewandowski, MD, FSIR

Closing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.

Ghassan Abou-Alfa, MD, Robert Lewandowski, MD, FSIR, and Amit Singal, MD discuss potential novel combination therapies including immune checkpoint inhibitors plus tyrosine kinase inhibitors plus local-regional therapeutic strategies.

Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.

Drs Abou-Alfa, Singal, and Lewandowski discuss use of immune checkpoint inhibitors and liver function.

The panel reviews the HIMALAYA and IMbrave-150 clinical trials of checkpoint inhibitor combination therapy strategies in advanced HCC.

A deeper dive on immune checkpoint inhibitors in HCC including review of the mechanisms of action of the IO agents.

A multidisciplinary panel discusses use of immune checkpoint inhibitors in patients with advanced HCC.

Drs Singal and Lewandowski review use of tyrosine kinase inhibitors, sorafenib and lenvatinib, and discuss trials that combined systemic therapy with chemoembolization.

Experts in hepatocellular carcinoma discuss treatment options for locally advanced disease.

Dr Singal reviews the Child-Pugh scoring system, then Dr Lewandowski discusses the importance of considering liver function as well as disease burden when selecting a treatment strategy.

The panel shares insight as to which patients might be candidates for curative therapies such as embolization techniques and liver transplant.

Ghassan Abou-Alfa, MD leads Robert Lewandowski, MD, FSIR, and Amit Singal, MD in a discussion of the main risk factors for hepatocellular carcinoma.